iTreg Cell Therapy for Osteogenesis Imperfecta Bone Remodeling

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for osteogenesis imperfecta (OI) do not effectively reduce fracture rates, prevent bone deformities, and minimize chronic pain, and long-term treatments have undesired side effects, necessitating alternative strategies for enhancing bone remodeling.

Innovation Solution

A composition comprising induced T regulatory cells (iTregs) and bone marrow cells, or iTreg conditioned medium, is administered to enhance bone remodeling, which includes the production of iTregs through incubation with anti-CD3 antibody, anti-CD28 antibody, IL-2, TGF-β, and retinoic acid, and may be combined with additional agents like bisphosphonates to treat OI.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If long-term treatment with drugs is used to treat osteogenesis imperfecta, then bone health is improved, but undesired side effects occur

Engineering Contradiction:

Improvebone healthVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces T regulatory cells as an intermediary biological agent that mediates the treatment effect. These cells act as a natural mediator that promotes bone remodeling through physiological mechanisms rather than direct pharmacological intervention, thereby achieving therapeutic benefits while avoiding drug-induced side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the chemical/pharmacological treatment system with a biological cell-based system. Instead of using drugs that chemically interact with bone tissue, the invention uses T regulatory cells that biologically regulate bone remodeling through cell-to-cell interactions and cytokine secretion, substituting a chemical mechanism with a biological one

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Ease of operation

If current therapies are used for osteogenesis imperfecta, then treatment is provided, but fracture rates are not effectively reduced and bone deformities are not prevented

Engineering Contradiction:

Improvetreatment availabilityVSAvoidfracture reduction efficacy

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent changes the fundamental parameter of treatment approach from pharmacological to cellular therapy. By introducing T regulatory cells that actively promote bone formation and remodeling, the treatment efficacy parameter is improved, enabling better fracture reduction and deformity prevention outcomes

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a composite therapeutic approach by combining T regulatory cells with bone marrow cells. This cellular composite works synergistically to enhance bone remodeling - T regulatory cells regulate the immune response and promote anabolic activity, while bone marrow cells provide osteoprogenitor cells, together achieving superior therapeutic effect

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS11975024B2T regulatory (Treg) cell transplantation in osteogenesis imperfecta (OI)

Publication Date: 2024.05.07 MUSC FOUNDATION FOR RESEARCH DEVELOPMENT(US)

AI summary

The present invention relates to compositions comprising induced T regulatory cells (iTregs), methods of making the compositions, and methods of using the compositions for enhancing bone remodeling in the treatment of Osteogenesis Imperfecta (OI).